S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:ACET

Adicet Bio (ACET) Stock Price, News & Analysis

$2.35
+0.02 (+0.86%)
(As of 03/28/2024 ET)
Today's Range
$2.31
$2.40
50-Day Range
$1.95
$3.38
52-Week Range
$1.10
$7.50
Volume
529,955 shs
Average Volume
1.81 million shs
Market Capitalization
$193.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.83

Adicet Bio MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
446.1% Upside
$12.83 Price Target
Short Interest
Bearish
7.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.57mentions of Adicet Bio in the last 14 days
Based on 14 Articles This Week
Insider Trading
Acquiring Shares
$7.50 M Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.72) to ($1.84) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.00 out of 5 stars

Medical Sector

409th out of 938 stocks

Pharmaceutical Preparations Industry

185th out of 417 stocks

ACET stock logo

About Adicet Bio Stock (NASDAQ:ACET)

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical trial for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-270 that is in preclinical stage for the treatment of renal cell carcinoma and potential solid tumor; and ADI-002, which is undergoing preclinical studies for the treatment of hepatocellular carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.

ACET Stock Price History

ACET Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Adicet Bio (NASDAQ:ACET) Stock Rating Upgraded by StockNews.com
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Adicet Bio’s Promising Drug Pipeline and Buy Rating Justification
Adicet Bio's (ACET) "Buy" Rating Reaffirmed at HC Wainwright
Adicet Bio (NASDAQ:ACET) Earns Outperform Rating from Wedbush
JMP Securities Keeps Their Hold Rating on Adicet Bio (ACET)
ACET Stock Earnings: Adicet Bio Meets EPS for Q4 2023
Adicet Bio: Q4 Earnings Insights
Adicet Bio, Inc Q4 loss drops in line with estimates
7 Top-Tier Penny Stocks for a Smart Bet
ACET Apr 2024 7.500 call
See More Headlines
Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Trading Companies & Distributors
Current Symbol
NASDAQ:ACET
CUSIP
00444610
CIK
2034
Fax
N/A
Employees
132
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.83
High Stock Price Target
$27.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+446.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-142,660,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$24.99 million
Book Value
$2.43 per share

Miscellaneous

Free Float
57,919,000
Market Cap
$193.05 million
Optionable
Optionable
Beta
1.87
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Chen  Schor BAMr. Chen Schor BA (Age 52)
    CPA, M.B.A., CEO, President & Director
    Comp: $899.58k
  • Dr. Aya Jakobovits Ph.D. (Age 68)
    Founder & Independent Director
    Comp: $40k
  • Dr. Blake Aftab Ph.D. (Age 43)
    Senior VP & Chief Scientific Officer
    Comp: $675.04k
  • Dr. Francesco Galimi M.D. (Age 56)
    Ph.D., Chief Medical Officer & Senior VP
    Comp: $680.37k
  • Mr. Brian Nicholas Harvey (Age 63)
    Chief Financial Officer
    Comp: $596.79k
  • Dr. Donald Healey Ph.D. (Age 62)
    Chief Technology Officer
  • Ms. Amy Locke
    Chief Human Resource Officer
  • Dr. Nancy L. Boman M.D.
    Ph.D., Senior VP & Chief Regulatory Officer

ACET Stock Analysis - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACET shares.
View ACET analyst ratings
or view top-rated stocks.

What is Adicet Bio's stock price target for 2024?

8 brokers have issued 12-month price targets for Adicet Bio's shares. Their ACET share price targets range from $5.00 to $27.00. On average, they predict the company's stock price to reach $12.83 in the next year. This suggests a possible upside of 446.1% from the stock's current price.
View analysts price targets for ACET
or view top-rated stocks among Wall Street analysts.

How have ACET shares performed in 2024?

Adicet Bio's stock was trading at $1.89 on January 1st, 2024. Since then, ACET shares have increased by 24.3% and is now trading at $2.35.
View the best growth stocks for 2024 here
.

When is Adicet Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our ACET earnings forecast
.

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) issued its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.69) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.03.

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).

Who are Adicet Bio's major shareholders?

Adicet Bio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include RTW Investments LP (5.89%), Vanguard Group Inc. (2.40%), Vanguard Group Inc. (2.40%), Norges Bank (0.61%), Nuveen Asset Management LLC (0.28%) and Dimensional Fund Advisors LP (0.22%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Carl L Gordon, Chen Schor, Don Healey, Francesco Galimi, Jay P Elliott, Orbimed Advisors Llc and Steve Dubin.
View institutional ownership trends
.

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACET) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners